Emerging Treatments for HDV Infection: What’s in Store and Why Are They Needed?
  • CME
  • CE

Approval of bulevirtide in Europe and promising clinical trial results with lonafarnib signal that new management options for patients with hepatitis delta are on the horizon.
Takeshi Saito, MD, PhD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: September 28, 2021 Expiration: September 27, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement best practices in screening and management for HDV in patients diagnosed with HBV infection

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Takeshi Saito, MD, PhD

Associate Professor of Medicine
Medicine, Division of Gastrointestinal and Liver Diseases
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Takeshi Saito, MD, PhD, has no relevant conflicts of interest to report.

Staff

Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.
Jessica Adams, PharmD, BCPS, AAHIVP

Scientific Director

Jessica Adams, PharmD, BCPS, AAHIVP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with or at risk of viral hepatitis.

Goal

The goal of this activity is to improve learners’ competence in addressing key challenges in the management of persons with or at risk of hepatitis B, hepatitis C, and/or hepatitis delta.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-167-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 28, 2021, through September 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Acknowledgements

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Brief Clinical Care Options (CCO) presentation on APASL guidance on limitations of current HCC surveillance recommendations in chronic HBV infection

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 7, 2021 Expired: October 6, 2022

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue